<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Research Article" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">iarjp</journal-id><journal-id journal-id-type="pubmed">IARJP</journal-id><journal-id journal-id-type="publisher">IARJP</journal-id><issn>2709-9512</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/iarjp.2021.v02i01.001</article-id><title-group><article-title>Metabolic Considerations in Prodrug Design: An Overview</article-title></title-group><contrib-group><contrib contrib-type="author"><name><given-names>SurajKumar</given-names><surname>sah</surname></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><given-names>Vivek</given-names><surname>Gupta</surname></name></contrib></contrib-group><aff-id id="aff-a" /><abstract>The review of Metabolic considerations in Prodrug design is a well-established dedication to the design of absolutely safe drugs by targeting the biopharmaceutical, physiochemical and pharmacokinetic properties. Its scope extends to the improving poor drug properties such as stability, permeability, solubility and toxicity by approaching through physical, chemical or biological ways. The review covers how metabolic consideration is helpful in prodrug design.</abstract></article-meta></front><body /><back /></article>